Patents by Inventor Hongkui Jin
Hongkui Jin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20060074024Abstract: A mammal with congestive heart failure is treated by administering to the mammal an effective amount of growth hormone. Treatment results in increased left ventricular cystolic pressure, increased left ventricular maximum, increased cardiac output, and increased stroke volume index. Treatment also results in reduced left ventricular end-diastolic pressure and reduced systemic vascular resistance. These measurements indicate improvement in cardiac function by increased ventricular contractility and decreased peripheral vascular resistance.Type: ApplicationFiled: November 28, 2005Publication date: April 6, 2006Inventors: Stuart Bunting, Ross Clark, Nancy Gillett, Hongkui Jin, Renhui Yang
-
Patent number: 6989364Abstract: The invention concerns the treatment of cardiac hypertrophy by interferon-gamma (IFN-?). Cardiac hypertrophy may result from a variety of diverse pathologic conditions, including myocardial infarction, hypertension, hypertrophic cardiomyopathy, and valvular regurgitation. The treatment extends to all stages of the progression of cardiac hypertrophy, with or without structural damage of the heart muscle, regardless of the underlying cardiac disorder.Type: GrantFiled: November 16, 2000Date of Patent: January 24, 2006Assignee: Genentech, Inc.Inventors: Hongkui Jin, Hsienwie Lu, Nicholas F. Paoni, Renhui Yang
-
Publication number: 20050171006Abstract: A mammal with congestive heart failure is treated by administering to the mammal an effective amount of growth hormone. Treatment results in increased left ventricular cystolic pressure, increased left ventricular maximum, increased cardiac output, and increased stroke volume index. Treatment also results in reduced left ventricular end-diastolic pressure and reduced systemic vascular resistance. These measurements indicate improvement in cardiac function by increased ventricular contractility and decreased peripheral vascular resistance.Type: ApplicationFiled: February 18, 2005Publication date: August 4, 2005Inventors: Stuart Bunting, Ross Clark, Nancy Gillett, Hongkui Jin, Renhui Yang
-
Publication number: 20050124541Abstract: A mammal with congestive heart failure is treated by administering to the mammal an effective amount of growth hormone. Treatment results in increased left ventricular cystolic pressure, increased left ventricular maximum, increased cardiac output, and increased stroke volume index. Treatment also results in reduced left ventricular end-diastolic pressure and reduced systemic vascular resistance. These measurements indicate improvement in cardiac function by increased ventricular contractility and decreased peripheral vascular resistance.Type: ApplicationFiled: May 18, 2004Publication date: June 9, 2005Inventors: Stuart Bunting, Ross Clark, Nancy Gillett, Hongkui Jin, Renhui Yang
-
Publication number: 20040180821Abstract: A mammal with congestive heart failure is treated by administering to the mammal an effective amount of growth hormone. Treatment results in increased left ventricular cystolic pressure, increased left ventricular maximum, increased cardiac output, and increased stroke volume index. Treatment also results in reduced left ventricular end-diastolic pressure and reduced systemic vascular resistance. These measurements indicate improvement in cardiac function by increased ventricular contractility and decreased peripheral vascular resistance.Type: ApplicationFiled: July 18, 2003Publication date: September 16, 2004Applicant: Genentech, Inc.Inventors: Stuart Bunting, Ross Clark, Nancy Gillett, Hongkui Jin, Renhui Yang
-
Publication number: 20040006014Abstract: A mammal with congestive heart failure is treated by administering to the mammal an effective amount of growth hormone. Treatment results in increased left ventricular cystolic pressure, increased left ventricular maximum, increased cardiac output, and increased stroke volume index. Treatment also results in reduced left ventricular end-diastolic pressure and reduced systemic vascular resistance. These measurements indicate improvement in cardiac function by increased ventricular contractility and decreased peripheral vascular resistance.Type: ApplicationFiled: November 4, 2002Publication date: January 8, 2004Applicant: Genentech, Inc.Inventors: Stuart Bunting, Ross Clark, Nancy Gillett, Hongkui Jin, Renhui Yang
-
Publication number: 20030045469Abstract: A mammal with congestive heart failure is treated by administering to the mammal an effective amount of growth hormone Treatment results in increased left ventricular cystolic pressure, increased left ventricular maximum, increased cardiac output, and increased stroke volume index Treatment also results in reduced left ventricular end-diastolic pressure and reduced systemic vascular resistance. These measurements indicate improvement in cardiac function by increased ventricular contractility and decreased peripheral vascular resistance.Type: ApplicationFiled: October 24, 2001Publication date: March 6, 2003Applicant: Genentech, Inc.Inventors: Stuart Bunting, Ross Clark, Nancy Gillett, Hongkui Jin, Renhui Yang
-
Patent number: 6187304Abstract: The invention concerns the treatment of cardiac hypertrophy by interferon-gamma (IFN-&ggr;). Cardiac hypertrophy may result from a variety of diverse pathologic conditions, including myocardial infarction, hypertension, hypertrophic cardiomyopathy, and valvular regurgitation. The treatment extends to all stages of the progression of cardiac hypertrophy, with or without structural damage of the heart muscle, regardless of the underlying cardiac disorder.Type: GrantFiled: March 19, 1999Date of Patent: February 13, 2001Assignee: Genentech, Inc.Inventors: Hongkui Jin, Hsienwie Lu, Nicholas F. Paoni, Renhui Yang
-
Patent number: 5935924Abstract: A mammal with congestive heart failure is treated by administering to the mammal an effective amount of growth hormone. Treatment results in increased left ventricular cystolic pressure, increased left ventricular maximum, increased cardiac output, and increased stroke volume index. Treatment also results in reduced left ventricular end-diastolic pressure and reduced systemic vascular resistance. These measurements indicate improvement in cardiac function by increased ventricular contractility and decreased peripheral vascular resistance.Type: GrantFiled: April 15, 1994Date of Patent: August 10, 1999Assignee: Genentech, Inc.Inventors: Stuart Bunting, Ross Clark, Nancy Gillett, Hongkui Jin, Renhui Yang
-
Patent number: 5661122Abstract: Methods of enhancing myocardial contractility and cardiac performance in a mammal with congestive heart failure are disclosed. In a first method a mammal with congestive heart failure is treated by administering to the mammal an effective amount of a combination of growth hormone (GH) and insulin-like growth factor (IGF-I). A second method comprises administering to the mammal an effective amount of a combination of GH and IGF-I in the presence of an ACE inhibitor. This method results in enhancement of myocardial contractility and cardiac performance above the level achieved with ACE inhibition alone. Preferably the mammal is a human.Type: GrantFiled: August 2, 1994Date of Patent: August 26, 1997Assignee: Genentech, Inc.Inventors: Ross G. Clark, Hongkui Jin, Nicholas F. Paoni, Renhui Yang
-
Patent number: 5610134Abstract: Methods of enhancing myocardial contractility and cardiac performance in a mammal with congestive heart failure are disclosed. In a first method a mammal with congestive heart failure is treated by administering to the mammal an effective amount of a combination of growth hormone (GH) and insulin-like growth factor (IGF-I). A second method comprises administering to the mammal an effective amount of a combination of GH and IGF-I in the presence of an ACE inhibitor. This method results in enhancement of myocardial contractility and cardiac performance above the level achieved with ACE inhibition alone. Preferably the mammal is a human.Type: GrantFiled: November 3, 1994Date of Patent: March 11, 1997Assignee: Genentech, Inc.Inventors: Ross G. Clark, Hongkui Jin, Nicholas F. Paoni, Renhui Yang